 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
CRUCELL NV ADS, (CRXL) Stock Rating Learn More
| Our Overall Rating on CRUCELL NV ADS, CRXL is Not Available | | Crucell N.V. engages in the discovery, development, and production of various biopharmaceutical products for the prevention and treatment of infectious diseases using its proprietary technologies. It develops vaccines and antibodies against influenza, West Nile virus, Ebola, malaria, tuberculosis, and rabies using PER.C6, AdVac, and MAbstract technologies. The companys PER.C6 technology encompasses a human cell line production system to develop biopharmaceutical products. Its AdVac technology is a recombinant vector technology that develops novel adenoviral-based products. Crucells MAbstract phage antibody display technology is used to discover disease associated molecules and develop human antibodies. The company licenses its technologies to pharmaceutical and biotechnology companies. Crucell is headquartered in Leiden, the Netherlands. | | Our Not Available Rating on CRXL was issued on 11/21/2008 |
CRUCELL NV ADS Technical Rating
|
|
|
|
